Improved survival and sustained clinical benefit with SU11248 (SU) in pts with GIST after failure of imatinib mesylate therapy in a phase III trial

Presenter: George Demetri, MD
Webcast from ASCO Gastrointestinal Cancers Symposium, January 2006.
After clicking link below, then click the "VIDEO" icon to the right of Dr. Demetri's name.
ASCO Webcast

Outcome of advanced GIST patients treated with imatinib mesylate: four-year follow-up of a randomized Phase II trial

Presenter: Charles Blanke, M.D.
ASCO Gastrointestinal Cancer Symposium, January 2006
Webcast (slides plus audio) available. After clicking the link below, then click the "VIDEO" icon to the right of Dr. Blanke's name.
ASCO video link
Poster of this presentation:
pdf of poster

Surgical management of advanced GIST following KIT-directed therapy

Authors: CP Raut, M Posner, J Desai, GD Demetri, JA Morgan, S George, D Zahrieh, CDM Fletcher, MM Bertagnolli
Slide show presented at CTOS, November 2005 (requires Powerpoint viewer)
CTOS

Targeting HSP90 in imatinib-resistant GIST

Authors: S Bauer, L Yu, GD Demetri, JA Fletcher
Slide show presented at CTOS, November 2005 (requires Powerpoint viewer)
CTOS

Advanced Gastrointestinal stromal tumor: molecular, pathological and clinical pattern in post-imatinib surgery

Authors: A Gronchi, M Fiore, R Bertulli, E Tamborini, P Collini, S Pilotti, C Mussi, P Coco, A Messina, S Stacchiotti, PG Casali
Slide show from CTOS, November 2005 (requires Powerpoint viewer, slow download)
CTOS

The Era of Molecularly Targeted Therapy: redefining the treatment of GIST

Presenter: Gianluca Fincato, MD
Western Europe Medical Affairs Director, Novartis
Date: June 2005, Dublin Ireland
Meeting: "New Horizons in Treating Cancer: Third International Conference for Organizations Representing People with CML or GIST"
View Fincato slides

Summary of ESMO Consensus on GIST and current research

Presenter: Peter Reichardt, MD
Date: June 2005, Dublin Ireland
Meeting: "New Horizons in Treating Cancer: Third International Conference for Organizations Representing People with CML or GIST"
view Reichardt slides

Special Plenary Lecture: Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GISTs

Presenter: Michael C. Heinrich, MD
ASCO, May 2005
After clicking the link below, click "Audio & Slides (below the abstract) to view presentation.
ASCO

Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST)

Presenter: Annick D. Van den Abbeele, MD
ASCO. May 2005
After clicking the link below, click either "Video" (to hear the talk) or "Slides" (to see slides without audio).
ASCO

Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST

Presenter: George D. Demetri, MD
ASCO, May 2005
After clicking link below, click "video" to hear and view presentation.
ASCO

Apoptotic and anti-vascular activity of imatinib in GIST patients

Presenter: Jonathan C. Trent, MD
AACO May 2005
Ater clicking link below, click "Video" to hear and view presentation.
ASCO

Results from a continuation trial of SU11248 in patients with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST)

Presenter: Robert G. Maki, MD, PhD
ASCO, May 2005
After clicking the link below, click either "Video" (to hear the talk) or "Slides" (to see slides without audio).
ASCO

Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S003

Presenter: Martin E Blackstein, MD, PhD, FACP
ASCO, May 2005
After clicking the link below, click either "Video" (to hear the talk) or "Slides" (to see slides without audio).
ASCO

Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results

Presenter: Ronald P. DeMatteo, MD
ASCO, May 2005
After clicking the link below, click either "Video" (to hear the talk) or "Slides" (to see slides without audio).
ASCO

FDG PET but not RECIST agrees with histologic response of soft tissue sarcoma to neoadjuvant chemotherapy

Presenter: Scott M. Schuetze, MD, PhD
ASCO, May 2005
After clicking the link below, click "Video" to hear and view presentation.
ASCO

Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors

Presenter: Lee Rosen, MD
ASCO, May 2005
After clicking the link below, click "Video" to hear and view presentation.
ASCO

Pharmacodynamic analysis of target receptor tyrosine kinase activity and apoptosis in GIST tumors responding to therapy with SU11248

ASCO, May 2005
Presenter: Darren W. Davis, Ph.D.
After clicking the link below, click "Video" to hear and view presentation.
ASCO

Rational Treatment Options for GIST: Gleevec, SU11248, RAD001 and Beyond

Webcast of presentation made in November 2004
by George D. Demetri, M.D.
at the Chemotherapy Foundation Symposium and Online Education Program, Mount Sinai School of Medicine.
After linking to the MSSM site, scroll down to the GI Cancers section and click beside the presentation title for Dr. Demetri's talk.
Chemotherapy Foundation Symposium MSSM

Systemic Management of Primary GIST

Webcast presented by Peter Reichardt, M.D.
in April 2004 to the Chinese Society of Clinical Oncology.
After linking to CSCO site, scroll down to the 11:10 am time slot on Saturday and click the link for Dr. Reichardt's presentation.
CSCO

GIST - Current and Future Clinical Trials

Milind Javle, MD
Slide presentation at the November 2004 NCCN GIST conference, Roswell Park Cancer Institute.
Roswell Park

18F-FDG PET -- a metabolic tool to grade treatment response in advanced gastrointestinal stromal tumor (GIST)

Dominick Lamonica, MD RPCI
Slide show presented at the November 2004 NCCN conference on GIST, Roswell Park Cancer Institute.
Roswell Park

Staging and surgical therapy for primary and recurrent gastrointestinal stromal tumors

John M. Kane III, MD
Slide presentation at the Nov. 2004 NCCN GIST conference, Roswell Park Cancer Institute.
RoswellPark

The pathology of gastrointestinal stromal tumors

Charles M. LeVea, MD PhD
Slide show presented at the November 2004 NCCN conference on GIST, Roswell Park Cancer Institute.
Roswell Park

Medical management of GIST

Michael Morse, MD
This slide show was presented at the November 2004 NCCN GIST conference, Roswell Park Cancer Institute.
Roswell Park

Interactive Tumor Board: Case no. 1: Gastric GIST

Benjamin F. Calvo, MD
slide show presented at the October 2004 annual clinical congress, American College of Surgeons
American College of Surgeons

Localized GIST in the Gleevec Era

Slide show by Ronald P. DeMatteo, M.D.
at the October 2004 Annual Clinical Congress, American College of Surgeons
American College of Surgeons

Prognostic factors for initial and late resistance to imatinib in patients with advanced GIST

Van Glabbeke M et al (group of authors from EORTC-ISG-AGIGT)
Slides (in Powerpoint software) from presentation at the Connective Tissue Oncology Society meeting, Nov. 2004.
http://www.ctos.org/meeting/2004/presentations/friday/vanGlabbeke.ppt

Acquired resistance to imatinib in GIST due to multiple kinase-domain mutations of KIT

Slides presented by Wardelmann et al
PowerPoint slides from Connective Tissue Oncology Society, Nov. 2004
Note that this may take a long time to download.
http://www.ctos.org/meeting/2004/presentations/friday/hohenberger.ppt

A comparison of patterns of tumor response to molecular-targeted therapy in GIST and chordoma

Casali et al
Powerpoint slides from presentation at CTOS, Nov, 2004
http://www.ctos.org/meeting/2004/presentations/friday/casali.PPT

The management of gastrointestinal stromal tumors and Recognizing and managing resistance to imatinib mesylate in patients with metastatic GIST

This webcast by Charles D. Blanke, MD was presented
on 6/19/2004 at the World Congress on Gastrointestinal Cancer.
It consists of two papers webcast back-to-back.
The second part was authored by George Demetri, MD, but Dr. Blanke gave the oral presentation in Dr. Demetri's absence.
NOTE that this webcast will not play in some browsers but does work fine in Internet Explorer.
View

Molecular events in gastrointestinal stromal tumors

This webcast was presented by Maria Debiec-Rychter, MD PhD
on 6/19/2004 at the World Congress on Gastrointestinal Cancer.
NOTE that this webcast works fine in Internet Explorer but does not play in some other browsers.
View

Is a PET scan a necessary tool in the treatment of gastrointestinal stromal tumors?

This webcast by Sigrid Stroobrants, MD PhD was presented
on 6/19/2004 at the World Congress on Gastrointestinal Stromal Tumors.
NOTE that this webcast works in Internet Explorer but does not play in some other browsers.
View

Long-term followup of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate

Webcast presentation by Charles Blanke, MD
ASCO 2004 Gastrointestinal Cancers Symposium
Once you have linked to the ASCO site, click the icon for "Video" to start the webcast.
ASCO

NCCN GIST Webcast

Dr. George Demetri and Dr. Ronald DeMatteo are this presenters in this comprehensive webcast summarizing a task force report from the National Comprehensive Cancer Network.

This webcast has been removed from the NCCN site. A limited number of copies of a CD-ROM containing the webcast may be available through NCCN.

Imatinib may enable complete resection in previously unresectable or metastatic GIST.

Presenter: Sebastian Bauer, MD
ASCO 2004 meeting abstract 9023
Link to AASCO site, then click "Slides" icon (look below abstract) to view slides.
ASCO

SU11248 can overcome imatinib resistance caused by diverse genomic mechanisms in patients with metastatic GIST

Presenter: George D. Demetri, MD
ASCO 2004 annual meeting abstract 3001
After linking to the ASCO page, click "Video" to start webcast (look below the abstract).
ASCO

Combination signal transduction inhibition: a phase I/II trial of ... RAD001 and imatinib in patients with GIST refractory to imatinib

Presenter:AT van Oosterom, MD PhD
2004 ASCO meeting abstract 3002
After linking to the ASCO page, click "Video" icon to start webcast (look below the abstract).
ASCO

Activity and tolerability of the multi-targeted tyrosine kinase inhibitor SUO11248 in patients with metastatic GIST refractory to imatinib mesylate

Presenter: Jayesh Desai, MD
ASCO 2004 Gastrointestinal Cancers Symposium abstract 7
After linking to ASCO page, click "video" icon to play the webcast (look below the abstract).
ASCO

Gastrointestinal Stromal Tumors

Presenter: AT van Oosterom, MD PhD
ASCO 2004 annual meeting.
Link to ASCO, then click icon for "Video" under the listing numbered as
"2. Gastrointestinal Stromal Tumors."
ASCO

Emerging Issues: biology and management of GIST

Presenter: S. Patel, MD
ASCO 2004 annual meeting
Link to the ASCO site, then scroll down the page to the last discussion entry by Dr. Patel, then click "Video" to the right of Dr. Patel's name to play the lecture.
ASCO

p53 mutations in GIST: pattern and prognostic significance

Presenter: M-H Ryu, MD
2004 ASCO meeting abstract 9026
Link to the ASCO page, then click "Slides" icon below the abstract to view slides (no sound).
ASCO

Use of CT as an early prognostic indicator of response to imatinib mesylate in patients with GIST

Presenter: CH Holdsworth, PhD
2004 ASCO meeting abstract 3011.
Link to ASCO site, then click "slides" to view.
ASCO

Safety and efficacy of percutaneous radio-frequency ablation in patients with metastatic GIST with clonal evolution of lesions refractory to imatinib

Presenter P. Dileo, MD
2004 ASCO meeting abstract 9024
Link to ASCO site, then click "slides" to view (look below abstract).
ASCO

Prognostic value of pathologic variables and mutations type in patients with complete surgical resection of GIST, a GEIS study

Presenter: J. Martin, MD
2004 ACSO meeting abstract 9029
Link to ASCO site, then click "slides" icon (look below abstract) to view.
ASCO

Effects of cessation of imatinib mesylate therapy in patients with imatinib-refractory GIST as visualized by FDG-PET scanning

Slide presentation by AD Van den Abbeele, MD
ASCO 2004 meeting abstract 3012
Link to ASCO site, then click "slides" icon (look below abstract) to view.
ASCO

Clonal evolution of resistance to imatinib in patients with GIST: molecular and radiologic evaluation of new lesions

Presenter: Jayesh Desai, MD
ASCO 2004 meeting abstract 3010
Link to ASCO site, then click "slides" icon (look below abstract) to view.
ASCO

Risk estimation with tumor size, serosal invasion and MIB-1 labeling index for GIST of the stomach

Slide presentation by H. Cho, MD
at 2004 ASCO meeting.
Link to ASCO site, then click "slides" to view.
ASCO - Virtual Meeting - Presentation View

ASCO 2003 Session on Sarcoma

This session includes several presentations on GIST.
Link to the ASCO site, then scroll down the page to find and select the desired presentations from this list.

Sarcoma
Robert G Maki, MD, PhD (Discussant)

Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results.
Abstract No: 3271
Robert S Benjamin, MD

Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): Interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG.
Abstract No: 3272
Jaap Verweij, MD, PhD

Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate.
Abstract No: 3273
George D. Demetri, MD

PDGFRA and KIT mutations correlate with the clinical responses to imatinib mesylate in patients with advanced gastrointestinal stromal tumors (GIST)
Abstract No: 3274
Michael C Heinrich, MD

Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST)
Abstract No: 3275
Jonathan A. Fletcher, MD

Below is the link to view the ASCO page containing the above presentation links:
ASCO 2003 Sarcoma session

Therapeutic options for gastrointestinal stromal tumors

Presenter: Charles D. Blanke, MD
ASCO 2003 meeting.
Link to the ASCO site, then click "Video" (look below abstract) to start webcast.
ASCO

Gastrointestinal stromal tumors: diagnosis, epidemiology, prognosis

Presenter: L-G Kindblom, MD
ASCO 2003 meeting.
Link to the ASCO site, then click "Video" (look to right of Dr. Kindblom's name)to start the webcast.
ASCO

Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal

Presenter: GD Demetri, MD
ASCO 2003 meeting abstract 3273.
Link to ASCO and click "slides" to view (look below abstract).
ASCO

Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST)

Presenter: JA Fletcher, MD
ASCO 2003 meeting abstract 3275.
Link to ASCO, then click "slides" to view (look below abstract).
ASCO

STI-571 in GI Stromal Tumors

Presenter: George D. Demetri, MD
2001 Chemotherapy Foundation Symposium and Online Education Program, Mount Sinai School of Medicine.
After linking to the MSSM site, scroll down to the "Novartis" section of the program and you will see the clicker to view the presentattion for Dr. Demetri.
Chemotherapy Foundation Symposium MSSM

Clinical Management of GIST: Understanding the New Paradigms

This is a CME publication covering key clinical issues in the management of GIST including highlights from the 2003 Connective Tissue Oncology Society annual meeting and the Helsinki Gist Symposium. It was released in April 2004. While not strictly a slide show, this booklet contains graphics from many different presentations by experts.
http://www.ctos.org/newsletter/GIST_Newsletter0404.pdf

Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI-571, in patients with unresectable or metastatic GISTs ...

Presenter: Charles Blanke, MD
ASCO 2001 meeting plenary lecture.
This was the first presentation about Gleevec trials for GIST.
Link to ASCO site, click "Video" to start the webcast (look to the right of Dr. Blanke's name).
ASCO